- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03863795
Online Survey in Studying Smoking Attitudes and Behaviors Among Current Smokers
Self-Affirmation in the Context of Stigma-Induced Identity Threat Among Smokers
Study Overview
Detailed Description
PRIMARY OBJECTIVES:
I. To examine if self-affirmation attenuates the effects of cigarette smoking stigmatization on smoking risk perceptions, pro-smoking beliefs, and intentions to change smoking behavior.
OUTLINE:
Participants are recruited and pre-screened via an online crowdsourcing program called Amazon Mechanical Turk (MTurk). Participants then respond to a one-time research survey over 20 minutes on SurveyGizmo, an on-line survey software platform.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- NCI Division of Cancer Control and Population Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- United States (US) adult smokers.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational (survey)
Participants are recruited and pre-screened via an online crowdsourcing program MTurk, and then respond to a one-time research survey over 20 minutes on SurveyGizmo, an on-line survey software platform
|
Respond to SurveyGizmo survey online
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quit Intentions
Time Frame: At the time of survey response within approximately 20 minutes
|
Single item assessed intentions to quit smoking, 'Are you considering quitting smoking during the next 6 months?' from the 2014-2015 Tobacco Use Supplement to the Current Population Survey (1=yes, plan to stop within the next 30 days; 2=yes, plan to stop within the next 6 months, but not within 30 days; 3=no, not thinking of quitting in the next 6 months; U.S. Census Bureau, 2016).
Response options were reverse scored so that higher scores indicated greater intentions to quit.
|
At the time of survey response within approximately 20 minutes
|
Intentions to Switch Completely to E-cigarettes
Time Frame: At the time of survey response within approximately 20 minutes
|
"How likely are you to switch completely from using regular cigarettes to electronic cigarettes in the next 6 months?' 1 (not at all likely) to 5 (extremely likely)
|
At the time of survey response within approximately 20 minutes
|
Intentions to Seek Cessation Counseling
Time Frame: At the time of survey response within approximately 20 minutes
|
How likely is it that in the next 6 months you will seek counseling/support to help you quit smoking?
Response options were 1 (not at all likely) to 5 (extremely likely).
|
At the time of survey response within approximately 20 minutes
|
Intentions to Reduce Smoking
Time Frame: At the time of survey response within approximately 20 minutes
|
How likely is it that in the next 6 months that you will reduce the number of cigarettes you smoke in a day?
Response options were 1 (not at all likely) to 5 (extremely likely).
|
At the time of survey response within approximately 20 minutes
|
Self-exempting Beliefs
Time Frame: At the time of survey response within approximately 20 minutes.
|
Deterministic beliefs regarding smoking behaviors were evaluated using the 18-item self-exempting beliefs scale (Oakes et al., 2004).Response options were 1 (strongly disagree) to 5 (strongly agree).
Items were averaged to create a composite measure of self-exempting beliefs with excellent interitem reliability, α = .91.
|
At the time of survey response within approximately 20 minutes.
|
Positive Cognitions About Smoking
Time Frame: At the time of survey response within approximately 20 minutes.
|
Five items assessed positive cognitions about smoking (Fotuhi et al., 2013).
Response options were 1 (strongly disagree) to 5 (strongly agree).
Items were averaged to create a composite measure of self-exempting beliefs with excellent interitem reliability, α = .91.
|
At the time of survey response within approximately 20 minutes.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Annette Kaufman, NCI Division of Cancer Control and Population Sciences
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NCI-2019-01325 (REGISTRY: CTRP (Clinical Trial Reporting Program))
- 19-NCI-00810 (OTHER: NCI Division of Cancer Control and Population Sciences)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCurrent Smoker | Cigarette Smoker | Currently Living With SmokerUnited States
-
Roswell Park Cancer InstituteNational Institute on Drug Abuse (NIDA); National Cancer Institute (NCI)CompletedCurrent Smoker | Healthy Subject | Cigarette SmokerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCurrent Every Day Smoker | Cigarette SmokerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCurrent Every Day Smoker | Cigarette SmokerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnCurrent Smoker | Malignant Neoplasm | Current Every Day Smoker | Cigarette SmokerUnited States
-
Hiroshima UniversityWakunaga Pharmaceutical Co., Ltd.Completed
-
Ohio State University Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA)RecruitingCurrent Every Day Smoker | Cigarette SmokerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedCurrent Every Day Smoker | Cigarette SmokerUnited States
-
M.D. Anderson Cancer CenterNational Institute on Drug Abuse (NIDA); National Cancer Institute (NCI)CompletedCurrent Every Day Smoker | Cigarette Smoker | StudentUnited States
-
University of NebraskaInstitute for Science and HealthCompleted
Clinical Trials on Survey Administration
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Boston UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHepatocellular CarcinomaUnited States
-
Thomas Jefferson UniversityRecruitingMalignant Head and Neck NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMalignant Vascular NeoplasmUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMelanoma | COVID-19 InfectionUnited States